tetano
Editor, Senior Moderator
Ann Acad Med Singap
. 2025 Apr 30;54(5):270-282.
doi: 10.47102/annals-acadmedsg.202535. Omicron SARS-CoV-2 outcomes in vaccinated individuals with heart failure and ischaemic heart disease
Liang En Wee[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Enoch Xueheng Loy[SUP] #[/SUP][SUP] 1 [/SUP], Jue Tao Lim[SUP] #[/SUP][SUP] 4 [/SUP], Yew Woon Chia[SUP] 4 5 6 [/SUP], Shir Lynn Lim[SUP] 6 7 8 [/SUP], Jonathan Yap[SUP] 2 9 [/SUP], Khung Keong Yeo[SUP] 2 9 [/SUP], Derek J Hausenloy[SUP] 2 6 10 11 [/SUP], Mark Yan Yee Chan[SUP] 6 7 [/SUP], David Chien Boon Lye[SUP] 1 4 6 12 [/SUP], Kelvin Bryan Tan[SUP] 1 2 4 13 14 [/SUP]
Affiliations
Introduction: Outcomes after SARS-CoV-2 Omicron infection in patients with heart failure (HF) and ischaemic heart disease (IHD) remain poorly defined.
Method: In a highly vaccinated cohort of adult Singapore citizens and permanent residents, we used Cox proportional hazards models (adjusted for sociodemographic variables and comorbidities) to compare the risks of Omicron infection, COVID-19- related hospitalisation, and severe COVID-19 between indivi-duals with HF or IHD and matched controls without these conditions.
Results: From national databases, we identified 15,426 HF patients matched 1:∼3 to 41,221 controls, and 110,442 IHD patients matched 1:∼2 to 223,843 controls. Over 80% of HF and IHD patients had received at least 3 vaccine doses. During the Omicron-predominant period, both HF and IHD cohorts demonstrated higher adjusted risks of COVID-19 hospitalisation compared with matched controls (HF: adjusted hazard ratio [aHR] 1.77, 95% confidence interval [CI] 1.65-1.90; IHD: aHR 1.21, 95% CI 1.17-1.26). Among those with at least 1 HF-or IHD-related admission in the prior year, hospitalisation risk was further elevated (HF: aHR 1.27, 95% CI 1.13-1.42; IHD: aHR 1.11, 95% CI 1.01-1.23). Receipt of ≥3 vaccine doses was associated with substantially lower risk of severe COVID-19 versus only 2 doses (HF: aHR 0.35, 95% CI 0.28-0.43; IHD: aHR 0.27, 95% CI 0.23-0.32). A fourth dose conferred additional reductions in infection and adverse outcomes, though CIs for infection overlapped with those for 3 doses.
Conclusion: During Omicron predominance, HF and IHD patients experienced greater risk of COVID-19 hospitalisation and severe COVID-19 versus matched controls. Booster vaccinations attenuated these risks. Individuals with recent HF/IHD admissions should be prioritised for receipt of booster vaccine doses.
Keywords: COVID-19; Omicron; SARS-CoV-2; boosters; cardiology; heart failure; infectious diseases; vaccination.
. 2025 Apr 30;54(5):270-282.
doi: 10.47102/annals-acadmedsg.202535. Omicron SARS-CoV-2 outcomes in vaccinated individuals with heart failure and ischaemic heart disease
Liang En Wee[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Enoch Xueheng Loy[SUP] #[/SUP][SUP] 1 [/SUP], Jue Tao Lim[SUP] #[/SUP][SUP] 4 [/SUP], Yew Woon Chia[SUP] 4 5 6 [/SUP], Shir Lynn Lim[SUP] 6 7 8 [/SUP], Jonathan Yap[SUP] 2 9 [/SUP], Khung Keong Yeo[SUP] 2 9 [/SUP], Derek J Hausenloy[SUP] 2 6 10 11 [/SUP], Mark Yan Yee Chan[SUP] 6 7 [/SUP], David Chien Boon Lye[SUP] 1 4 6 12 [/SUP], Kelvin Bryan Tan[SUP] 1 2 4 13 14 [/SUP]
Affiliations
- PMID: 40471109
- DOI: 10.47102/annals-acadmedsg.202535
Introduction: Outcomes after SARS-CoV-2 Omicron infection in patients with heart failure (HF) and ischaemic heart disease (IHD) remain poorly defined.
Method: In a highly vaccinated cohort of adult Singapore citizens and permanent residents, we used Cox proportional hazards models (adjusted for sociodemographic variables and comorbidities) to compare the risks of Omicron infection, COVID-19- related hospitalisation, and severe COVID-19 between indivi-duals with HF or IHD and matched controls without these conditions.
Results: From national databases, we identified 15,426 HF patients matched 1:∼3 to 41,221 controls, and 110,442 IHD patients matched 1:∼2 to 223,843 controls. Over 80% of HF and IHD patients had received at least 3 vaccine doses. During the Omicron-predominant period, both HF and IHD cohorts demonstrated higher adjusted risks of COVID-19 hospitalisation compared with matched controls (HF: adjusted hazard ratio [aHR] 1.77, 95% confidence interval [CI] 1.65-1.90; IHD: aHR 1.21, 95% CI 1.17-1.26). Among those with at least 1 HF-or IHD-related admission in the prior year, hospitalisation risk was further elevated (HF: aHR 1.27, 95% CI 1.13-1.42; IHD: aHR 1.11, 95% CI 1.01-1.23). Receipt of ≥3 vaccine doses was associated with substantially lower risk of severe COVID-19 versus only 2 doses (HF: aHR 0.35, 95% CI 0.28-0.43; IHD: aHR 0.27, 95% CI 0.23-0.32). A fourth dose conferred additional reductions in infection and adverse outcomes, though CIs for infection overlapped with those for 3 doses.
Conclusion: During Omicron predominance, HF and IHD patients experienced greater risk of COVID-19 hospitalisation and severe COVID-19 versus matched controls. Booster vaccinations attenuated these risks. Individuals with recent HF/IHD admissions should be prioritised for receipt of booster vaccine doses.
Keywords: COVID-19; Omicron; SARS-CoV-2; boosters; cardiology; heart failure; infectious diseases; vaccination.